Immuneering Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:IMRX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
23 Jun 26	BuyUS$10,948	Benjamin Zeskind	Individual	2,400	US$4.56
15 Jun 26	BuyUS$25,045	Brett Hall	Individual	6,035	US$4.15
16 Jan 26	BuyUS$24,990	Harold Brakewood	Individual	5,250	US$4.76
15 Jan 26	BuyUS$10,502	Brett Hall	Individual	2,298	US$4.57
15 Jan 26	BuyUS$101,041	Thomas Schall	Individual	21,645	US$4.67
13 Jan 26	BuyUS$10,906	Leah Neufeld	Individual	2,626	US$4.15
12 Jan 26	BuyUS$86,904	Peter Feinberg	Individual	20,000	US$4.35
03 Oct 25	BuyUS$50,025	Peter Feinberg	Individual	7,500	US$6.67
01 Oct 25	BuyUS$6,966	Michael Bookman	Individual	1,020	US$6.83
01 Oct 25	BuyUS$5,103	Leah Neufeld	Individual	800	US$6.38
01 Oct 25	BuyUS$1,917	Mallory Morales	Individual	300	US$6.39
30 Sep 25	BuyUS$52,730	Peter Feinberg	Individual	7,500	US$7.03
29 Sep 25	BuyUS$35,900	Peter Feinberg	Individual	5,000	US$7.18

Insider Trading Volume

Insider Buying: IMRX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMRX?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	2,708,559	4.19%
Private Companies	3,646,304	5.64%
Individual Insiders	9,132,545	14.1%
General Public	22,064,023	34.1%
Institutions	27,145,971	42%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 79.8%.

Top Shareholders

Top 25 shareholders own 58.77% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15%	FMR LLC	9,697,938	US$41.6m	0.13%	no data
5.64%	Hbm Healthcare Investments (Cayman) Ltd.	3,646,304	US$15.6m	0%	no data
4.96%	Benjamin Zeskind	3,210,179	US$13.8m	0.07%	no data
4.28%	Seth Merrin	2,770,386	US$11.9m	0%	no data
4.19%	Sanofi	2,708,559	US$11.6m	0%	0.74%
3.54%	Vanguard Capital Management, LLC	2,288,341	US$9.8m	0%	no data
3.09%	Marshall Wace LLP	1,996,585	US$8.6m	180%	0.01%
2.83%	T. Rowe Price Group, Inc.	1,829,188	US$7.8m	-8.26%	no data
2.33%	BlackRock, Inc.	1,507,258	US$6.5m	3.83%	no data
1.79%	Peter Feinberg	1,161,064	US$5.0m	1.75%	no data
1.78%	Robert Carpenter	1,148,839	US$4.9m	0%	no data
1.7%	Millennium Management LLC	1,102,712	US$4.7m	2,070%	no data
0.99%	Geode Capital Management, LLC	637,944	US$2.7m	3.21%	no data
0.84%	Occam Crest Management LP	545,098	US$2.3m	9.35%	1.32%
0.69%	Citadel Advisors LLC	447,278	US$1.9m	394%	no data
0.62%	Connor, Clark & Lunn Investment Management Ltd.	400,363	US$1.7m	202%	no data
0.59%	Brett Hall	382,531	US$1.6m	1.6%	no data
0.58%	Summit Equities, Inc.	376,749	US$1.6m	0%	0.02%
0.58%	UBS Asset Management AG	376,284	US$1.6m	97.7%	no data
0.51%	The Goldman Sachs Group, Inc.	327,655	US$1.4m	2.77%	no data
0.5%	Vanguard Fiduciary Trust Company	322,038	US$1.4m	0%	no data
0.46%	Burkehill Global Management, LP	300,000	US$1.3m	0%	0.07%
0.46%	Morgan Stanley	296,067	US$1.3m	-39.5%	no data
0.43%	Southport Management, L.L.C.	277,501	US$1.2m	0%	4.49%
0.42%	State Street Global Advisors, Inc.	268,520	US$1.2m	-88.8%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/21 06:45
End of Day Share Price	2026/07/21 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immuneering Corporation is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Li Wang Watsek	Cantor Fitzgerald & Co.
Yevgeniya Livshits	Chardan Capital Markets, LLC
Michael Yee	Jefferies LLC